Breaking News Instant updates and real-time market news.

KO

Coca-Cola

$49.78

0.13 (0.26%)

, DUK

Duke Energy

$89.60

-0.64 (-0.71%)

20:25
02/13/19
02/13
20:25
02/13/19
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include Coca-Cola (KO), consensus 43c... Duke Energy (DUK), consensus 89c... CME Group (CME), consensus $1.72... Waste Management (WM), consensus $1.06... Zoetis (ZTS), consensus 77c... PPL (PPL), consensus 49c... TransUnion (TRU), consensus 63c... BorgWarner (BWA), consensus $1.07... Six Flags (SIX), consensus 28c... Bloomin' Brands (BLMN), consensus 26c... Yeti (YETI), consensus 35c... Avon Products (AVP), consensus 7c.

KO

Coca-Cola

$49.78

0.13 (0.26%)

DUK

Duke Energy

$89.60

-0.64 (-0.71%)

CME

CME Group

$180.41

1.5 (0.84%)

WM

Waste Management

$98.55

-0.12 (-0.12%)

ZTS

Zoetis

$88.24

0.67 (0.77%)

PPL

PPL Corp.

$30.91

-0.1 (-0.32%)

TRU

TransUnion

$64.45

1.195 (1.89%)

BWA

BorgWarner

$40.41

0.26 (0.65%)

SIX

Six Flags

$63.84

0.55 (0.87%)

BLMN

Bloomin' Brands

$19.31

0.04 (0.21%)

YETI

Yeti

$18.66

0.25 (1.36%)

AVP

Avon Products

$2.90

0.16 (5.84%)

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 14

    Feb

  • 18

    Feb

  • 03

    Mar

  • 04

    Mar

  • 08

    May

  • 14

    May

KO Coca-Cola
$49.78

0.13 (0.26%)

12/13/18
UBSW
12/13/18
DOWNGRADE
Target $51
UBSW
Neutral
Coca-Cola assumed with a Neutral from Buy at UBS
UBS analyst Sean King downgraded Coca-Cola to Neutral while raising his price target for the shares to $51 from $50 after assuming coverage of the name. The analyst sees "moving parts" but says this is "not a new Coke."
01/22/19
GUGG
01/22/19
NO CHANGE
Target $53
GUGG
Buy
Coca-Cola remains best Food and Beverage idea at Guggenheim
While rolling out coverage of five names in Food and Beverage space, Guggenheim analyst Laurent Grandet says Coca-Cola (KO) remains his best idea. The analyst boosted his price target for the shares to $53 from $52 and keeps a Buy rating on the name. Coca-Cola is "innovating like never before and acquiring to fill white spaces," Grandet tells investors in a research note on the sector. He sees the company's organic sales growth accelerating to 4.4%, 4.9% and 5.0% in fiscal 2018, 2019 and 2020, respectively, as "beverage peers slow to 3%."
12/13/18
12/13/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Coca-Cola (KO) assumed with a Neutral from Buy at UBS with analyst Sean King saying he sees "moving parts" but says this is "not a new Coke." 2. FireEye (FEYE) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Melissa Franchi citing the stock's recent relative outperformance with the shares up 20% in the past three months versus the average software name being down 9%. 3. Sabre (SABR) downgraded to Hold from Buy at Deutsche Bank with analyst Ashish Sabadra saying he expects the company's global distribution system growth to moderate in 2019. 4. Weatherford (WFT) downgraded to Underperform from Market Perform at Raymond James with analyst J. Marshall Adkins saying he expects Weatherford's upcoming maturity "wall" to push into restructuring and result in an extreme cost to the company's restructured interest payments. 5. Argo Group (ARGO) downgraded to Market Perform from Outperform at Keefe Bruyette. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/08/19
RHCO
01/08/19
UPGRADE
Target $65
RHCO
Buy
Monster Beverage upgraded to Buy from Hold at SunTrust
SunTrust analyst William Chappell upgraded Monster Beverage (MNST) to Buy from Hold and raised his price target to $65 from $50, also raising his FY19 EPS view to $2.05 from $1.92. The analyst notes that after the recent declines in input costs and the "successful U.S. pricing actions", consensus expectations for the stock are too low, while the concerns over its partnership with Coca-Cola (KO) and challenges around growth in China are "overblown". After an 11% correction following Q3 earnings, Chappell believes that Monster Beverage shares offer an "attractive entry" opportunity.
DUK Duke Energy
$89.60

-0.64 (-0.71%)

01/09/19
01/09/19
DOWNGRADE
Target $87

Neutral
Duke Energy downgraded to Neutral on valuation, pipeline risks at BofA/Merrill
As previously reported, BofA/Merrill downgraded Duke Energy to Neutral from Buy and trimmed its price target to $87 from $88. Analyst Julien Dumoulin-Smith cites valuation, potential further dleays and cost overruns for the Atlantic Coast Pipeline, and limited near-term catalysts for the downgrade.
01/09/19
BOFA
01/09/19
DOWNGRADE
BOFA
Neutral
Duke Energy downgraded to Neutral from Buy at BofA/Merrill
07/23/18
07/23/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Duke Energy (DUK) upgraded to Neutral from Underweight at JPMorgan with analyst Christopher Turnure saying execution risk is priced into the shares at current levels and the company's visibility is improved following recent regulatory outcomes. 2. SunTrust (STI) upgraded to Buy from Neutral at B. Riley FBR with analyst Steve Moss citing the company's better outlook for revenue growth and efficiency improvement following its "good" Q2 results. 3. Cleveland-Cliffs (CLF) upgraded to Overweight from Neutral at JPMorgan with analyst Michael Gambardella citing the company's "strong" U.S. iron ore earnings momentum and the removal of an overhang with the Asia Pacific Iron Ore sale. 4. Delphi Technologies (DLPH) upgraded to Outperform from Perform at Oppenheimer with analyst Noah Kaye saying that trade risks, peak U.S. SAAR concerns, light duty diesel decline and potential long-term disruption from electrification have all contributed to a tempest of negative sentiment on the auto suppliers. 5. Essex Property Trust (ESS) upgraded to Market Perform at Raymond James. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/24/18
HOWW
07/24/18
INITIATION
Target $85
HOWW
Outperform
Duke Energy reinstated with an Outperform at Scotia Howard Weil
Scotia Howard Weil analyst Andrew Weisel reinstated Duke Energy with an Outperform and $85 price target.
CME CME Group
$180.41

1.5 (0.84%)

01/29/19
DBAB
01/29/19
NO CHANGE
DBAB
Exchange stocks should be bought on any weakness, says Deutsche Bank
Deutsche Bank analyst Brian Bedell recommends buying the stock of Exchanges on any weakness. There may some additional downside risk upon earnings reports as investors revise Q1 estimates down to reflect the slow volume start to the year, Bedell tells investors in a research note. However, he recommends using any weakness as a buying opportunity given his view that the exchange stocks are best positioned to outperform in the later stages of a market cycle.
12/04/18
LEHM
12/04/18
INITIATION
Target $210
LEHM
Overweight
CME Group reinstated with an Overweight at Barclays
Barclays analyst Jeremy Campbell reinstated coverage of CME Group with an Overweight rating and $210 price target. The analyst believes a premium price-to-earnings multiple is warranted and sustainable as CME is a "defensive financial with no credit exposure."
01/11/19
BOFA
01/11/19
DOWNGRADE
Target $191
BOFA
Neutral
CME Group downgraded to Neutral citing valuation at BofA/Merrill
BofA/Merrill analyst Michael Carrier downgraded CME Group to Neutral from Buy and lowered his price target to $191 from $200 citing full valuation and difficult 2019 comps.
01/22/19
SBSH
01/22/19
NO CHANGE
SBSH
Citi upgrades ICE to Buy, puts 'Upside Catalyst Watch' on CME
Citi analyst Ben Herbert upgraded IntercontinentalExchange (ICE) to Buy from Neutral and raised his price target for the shares to $86 from $80. The analyst also placed a "30 Day Upside Catalyst Watch" on his top pick CME Group (CME). He lowered his price target for those shares to $210 from $220 and keeps a Buy rating on the name. On IntercontinentalExchange, the analyst sees a more attractive valuation following the recent pullback and a more favorable volume outlook in 2019. Further, he thinks Data momentum drives an upward bias to revenue estimates in 2019 and 2020. For CME, Herbert expects a favorable NEX Group update relating to margins and revenue opportunities when the company reports Q4 earnings.
WM Waste Management
$98.55

-0.12 (-0.12%)

01/10/19
UBSW
01/10/19
UPGRADE
UBSW
Buy
Waste Management upgraded to Buy from Neutral at UBS
01/10/19
UBSW
01/10/19
UPGRADE
Target $103
UBSW
Buy
Waste Management upgraded to Buy with $103 target at UBS
UBS analyst Jon Windham upgraded Waste Management (WM) to Buy from Neutral and raised his price target for the shares to $103 from $90. The analyst believes increasing equity cash returns and Waste's "relatively lower" 2.4 times net debt to EBITDA will drive "more defensive relative performance in 2019." The stock trades at a 50 basis point free cash flow yield discount to Republic Services (RSG), Windham tells investors in a research note. The analyst sees potential for this gap to narrow after Waste Management's board recently authorized a 20% increase in its share buyback program.
02/04/19
KEYB
02/04/19
INITIATION
KEYB
Overweight
Waste Management initiated with an Overweight at KeyBanc
02/04/19
KEYB
02/04/19
INITIATION
KEYB
Overweight
Waste Management initiated with an Overweight at KeyBanc
KeyBanc analyst Sean Eastman initiated Waste Management with an Overweight rating and $112 price target. The analyst called Waste Management a "high-quality industry bellwether" and believes "ongoing operational improvements" position the company for "ever improving returns to support a disciplined and shareholder-friendly capital allocation strategy through the cycle."
ZTS Zoetis
$88.24

0.67 (0.77%)

11/12/18
BMOC
11/12/18
NO CHANGE
Target $93
BMOC
Market Perform
Zoetis price target raised to $93 from $86 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Zoetis to $93 after its Q3 earnings beat and raised FY18 guidance. The analyst acknowledges that the company's "commercial and R&D execution have been excellent", leading to its premium valuation. Arfaei keeps his Market Perform on Zoetis however, noting that in spite of its performance amid the reasonably high expectations, the company's insufficient pipeline visibility and premium valuation warrant a neutral stance.
02/12/19
CLVD
02/12/19
NO CHANGE
CLVD
Buy
Zoetis channel feedback positive on 2019, says Cleveland Research
Cleveland Research analyst Rob Eich said the firm's feedback from the channel indicates quarterly trends were mixed for Zoetis but that 2019 looks positive due to strong share gains and continued new product strength. The analyst, who added that his work points to Zoetis having recently won a contract with a U.K. hospital chain that has over 500 vets, keeps a Buy rating on Zoetis shares.
01/23/19
UBSW
01/23/19
INITIATION
Target $86
UBSW
Neutral
Zoetis initiated with a Neutral at UBS
UBS analyst Navin Jacob started Zoetis with a Neutral rating and $86 price target. The company's strong Fundamentals are offset by the current valuation, the analyst says.
12/19/18
BMOC
12/19/18
NO CHANGE
Target $32
BMOC
Market Perform
Elanco price target lowered to $32 from $37 at BMO Capital
BMO Capital analyst Alex Arfaei lowered his price target on Elanco (ELAN) to $32 and kept his Market Perform rating, saying its FY19 guidance was "modestly below" his expectations and that he doubts that the management is being conservative. The analyst also cites "significant uncertainties" in 2020 related to competitor's products and the company's R&D productivity, also lowering his FY19 EPS view to $1.13 from $1.22. Arfaei believes that the market valuation on Elanco similar to Zoetis (ZTS) is "premature" based on the "important differences in revenue growth potential, product mix, and execution track record" of the two companies.
PPL PPL Corp.
$30.91

-0.1 (-0.32%)

02/07/19
02/07/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PPL Corp. (PPL) downgraded to In Line from Outperform at Evercore ISI. 2. Essex Property Trust (ESS) downgraded to Hold from Buy at Jefferies with analyst Omotayo Okusanya saying the fundamental rent growth outlook for the company remains solid as job growth on the West Coast continues to outpace the rest of the nation. 3. Omega Healthcare (OHI) downgraded to Hold from Buy at Stifel with analyst Chad Vanacore citing valuation. 4. FormFactor (FORM) downgraded to Hold from Buy at Craig-Hallum with analyst Christian Schwab saying at current share price levels, he sees limited upside in the near-term, and notes that management has limited visibility regarding memory demand in the current environment. 5. Dunkin' Brands (DNKN) downgraded to Neutral from Buy at Kalinowski. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/06/19
EVER
02/06/19
DOWNGRADE
Target $30.5
EVER
In Line
PPL Corp. downgraded to In Line from Outperform at Evercore ISI
Evercore ISI analyst Greg Gordon downgraded PPL Corp to In Line with a price target of $30.50.
01/14/19
01/14/19
DOWNGRADE
Target $28

Underperform
PPL Corp. downgraded to Underperform at BofA/Merrill on continued U.K. pressures
As previously reported, BofA/Merrill analyst Julien Dumoulin-Smith downgraded PPL Corp. to Underperform from Neutral and lowered his price target on the shares to $28 from $29. The analyst cited PPL's recent outperformance, which he believes was unwarranted against what will likely be a challenging year end call. Management is expected to roll forward its long-term EPS guidance, currently 5%-6%, to 2021 where he sees just a 3.5% CAGR at best, one of the lower offerings across the large cap complex.
01/14/19
BOFA
01/14/19
DOWNGRADE
BOFA
Underperform
PPL Corp. downgraded to Underperform from Neutral at BofA/Merrill
TRU TransUnion
$64.45

1.195 (1.89%)

11/30/18
LEHM
11/30/18
UPGRADE
Target $225
LEHM
Overweight
Barclays upgrades Fair Isaac to Overweight following recent pullback
Barclays analyst Manav Patnaik upgraded Fair Isaac (FICO) to Overweight from Equal Weight and raised his price target for the shares to $225 from $200. The analyst says his constructive view on the stock comes on the back of the recent pullback as well as his appreciation of the company's evolution as a Software name. Patnaik prefers shares of Fair Isaac and TransUnion (TRU) over Equifax (EFX) and Dun & Bradstreet (DNB).
10/24/18
10/24/18
UPGRADE
Target $82

Overweight
TransUnion upgraded to Overweight following pullback at Atlantic Equities
As previously reported, Atlantic Equities analyst Kunaal Malde upgraded TransUnion to Overweight from Neutral, noting that the stock has fallen 15% from its highs despite no real change to the company's outlook. The company's issues with certain clients, particularly in healthcare, that lead to a moderation in organic growth look transitory, Malde said. Noting that credit remains healthy, the analyst said he continues to estimate mid-teens EPS growth over the medium term. Malde keeps an $82 price target on TransUnion shares.
12/07/18
FBCO
12/07/18
INITIATION
Target $70
FBCO
Neutral
TransUnion initiated with a Neutral at Credit Suisse
Target $70.
10/24/18
BARD
10/24/18
NO CHANGE
Target $81
BARD
Outperform
TransUnion weakness a buying opportunity, says Baird
Baird analyst Jeffrey Meuler said he likes TransUnion shares a lot following their recent pullback. He said organic growth remains strong and broad-based, and the Q3 underlying margin performance was very strong. Meuler reiterated his Outperform rating and $81 price target on TransUnion shares.
BWA BorgWarner
$40.41

0.26 (0.65%)

12/13/18
DBAB
12/13/18
INITIATION
DBAB
Deutsche Bank initiates auto sector with cautious view
Deutsche Bank analyst Emmanuel Rosner initiated coverage of the auto sector with a cautious view. Rosner said this view reflects "cyclical and macro risks for the industry across the globe, as well as secular pressure from the shift towards electrified vehicles and autonomous shared mobility." The analyst favors suppliers with "secular growth potential through adoption of their technology," and as such, initiated Aptiv (APTV) and BorgWarner (BWA) with Buy ratings. Rosner also saw value in "suppliers that can maintain organic growth through share gains or favorable end-markets, and have favorable operational track record," and as such, initiated Dana Inc (DAN) and Lear Corporation (LEA) with Buy ratings. The analyst also started General Motors (GM) and Ford (F) with Buy ratings, citing "large potential upside from restructuring and portfolio decisions, favorable product mix and cycle, and value optionality from their efforts in Mobility." Rosner said he was negative on stocks facing secular pressure or market share loss, adding that he sees downside risk in Autoliv (ALV) and Veoneer (VNE), which he initiated with Sell ratings.
01/07/19
MSCO
01/07/19
NO CHANGE
MSCO
Morgan Stanley sees most, if not all, auto suppliers guiding below consensus
Ahead of the Detroit auto show, Morgan Stanley analyst Armintas Sinkevicius said he expects that most, if not all, auto suppliers will provide 2019 guidance that is lower than consensus. He sees the most downside risk to Visteon (VC) and Adient (ADNT), estimating that they may guide adjusted EBITDA 6.4% and 5.0% below consensus, respectively. Not everyone will provide guidance at the show, as American Axle (AXL) and Delphi Technologies (DLPH) gave guidance with Q3 earnings and Aptiv (APTV) and BorgWarner (BWA) plan to wait for Q4 earnings, added Sinkevicius. He estimates that, on average, the auto suppliers will guide to 1.5% revenue growth and -25 bps of margin contraction in 2019, adding that his concern is that the guidance provided at Detroit may not sufficiently de-risk figures. Others in the space include Lear (LEA), Tenneco (TEN) and Magna (MGA).
01/28/19
BMOC
01/28/19
NO CHANGE
BMOC
BorgWarner, Gentherm, Visteon, Autolive price targets raised at BMO Capital
BMO Capital analyst Richard Carlso is turning more bullish on the auto and mobility equipment industry, saying the sentiment from the most recent CES, Detroit Auto Show, and GM's (GM) Capital Markets Day events has shifted his outlook from "cautious" to "cautiously optimistic". The analyst attributes the snap-back rally in the sector stocks' prices to increased optimism over the impact of lingering trade issues and outlooks from companies that have so far updated on their Q4 performance, all of which suggested that the 2018-end declines were overextended. Carlson is raising his price target on Autoliv (ALV) to $84 from $79, on Gentex (GNTX) to $27 from $24, on Aptiv (APTV) to $84 from $74, on Veoneer (VNE) to $41 from $36, on BorgWarner (BWA) to $49 from $44, and on Visteon (VC) to $91 from $84.
02/13/19
GHSC
02/13/19
INITIATION
GHSC
Neutral
BorgWarner initiated with a Neutral at Seaport Global
SIX Six Flags
$63.84

0.55 (0.87%)

12/12/18
12/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Foamix (FOMX) initiated with a Buy at BofA/Merrill. 2. Jazz Pharmaceuticals (JAZZ) initiated with an Outperform at Oppenheimer while GW Pharmaceuticals (GWPH) was initiated with a Perform. 3. Six Flags (SIX) initiated with a Buy at Berenberg. 4. iQIYI (IQ) initiated with a Hold at HSBC. 5. Intercept (ICPT), Viking Therapeutics (VKTX), and Galmed (GLMD) were initiated with a Buy at B. Riley FBR, while Madrigal Pharmaceuticals (MDGL) initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/17/19
01/17/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Amicus (FOLD) upgraded to Buy from Neutral at Citi with analyst Mohit Bansal saying in recent months, the expectations on accelerated approval for AT-GAA have come down. 2. CBS (CBS) upgraded to Buy from Neutral at MoffettNathanson. 3. SeaWorld (SEAS) and Six Flags (SIX) upgraded to Outperform from Market Perform at Wells Fargo. 4. Dermira (DERM) upgraded to Market Perform from Underperform at Raymond James. 5. Penn National (PENN) upgraded to Buy from Neutral at Nomura Instinet with analyst Harry Curtis saying he sees "key catalysts" in the form of positive estimate revisions, free cash generation of approximately $3.10 per share this year and $4.50 next, as well as both leverage reduction and share repurchases. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/17/19
WELS
01/17/19
UPGRADE
Target $32
WELS
Outperform
Six Flags upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Timothy Conder upgraded Six Flags to Outperform from Market Perform, with a $32 price target. The analyst's confidence is increased as the turnaround strategy and cost savings continue to generate greater than anticipated upside, $475-$500M 2020 Adjusted EBITDA goal appears reasonable, and improving free cash flow supports disciplined capital allocation, further deleveraging and potential return of capital.
01/17/19
OPCO
01/17/19
NO CHANGE
Target $68
OPCO
Outperform
Six Flags price target lowered to $68 from $80 at Oppenheimer
Oppenheimer analyst Ian Zaffino lowered his price target for Six Flags to $68 from $80 to reflect peer multiple compression and lower expectations for the higher-multiple, and assetlight International business. The analyst anticipates "solid" Q4 results, helped by favorable weather comps and 20% more operating days from the Mexican Waterpark, Magic Mountain, Chicago HIP and EPR. Further, the stock tends to outperform in the offseason and, despite its recent run since December lows, the performance is still below the 8-year average, he contended. With that said, Zaffino tempers his expectations for International, owing to Chinese economic weakness and Dubai delays. He reiterates an Outperform rating on the shares.
BLMN Bloomin' Brands
$19.31

0.04 (0.21%)

01/08/19
JPMS
01/08/19
UPGRADE
Target $23
JPMS
Overweight
Bloomin' Brands upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst John Ivankoe upgraded Bloomin' Brands to Overweight with an unchanged price target of $23. Despite sustained traffic outperformance relative to peers, Bloomin' shares have remained below $20, Ivankoe tells investors in a research note. The analyst believes "now is the right time to take risk to pursue returns in casual dining."
01/23/19
01/23/19
NO CHANGE

Four Corners Property Trust acquires Outback Steakhouse restaurant for $3.9M
Four Corners Property Trust (FCPT) acquired an Outback Steakhouse restaurant in New Mexico for $3.9M. The property was acquired through a sale-leaseback transaction and will operate under a new triple-net lease with Cerca Trova, the largest domestic franchisee in the Bloomin' Brands (BLMN) system. The lease has 20 years of initial term and rent increases of 10% every five years during the initial term. The capitalization rate is consistent with past transactions.
02/08/19
BOFA
02/08/19
DOWNGRADE
BOFA
Underperform
Bloomin' Brands downgraded to Underperform from Neutral at BofA/Merrill
02/08/19
02/08/19
DOWNGRADE
Target $17

Underperform
Bloomin' Brands downgraded to Underperform ahead of earnings at BofA/Merrill
As previously reported, BofA Merrill Lynch analyst Gregory Francfort downgraded Bloomin' Brands to Underperform from Neutral as he cut his 2019 EBITDA and EPS estimates ahead of the company's earnings report, due next Thursday. Bloomin', like peers, has reinvested in its product over the past three years, which should support a positive sales gap compared to the industry, said Francfort. However, he believes the company's results and guidance could "materially disappoint" given ongoing cost headwinds facing the industry coupled with cost step-ups that are specific to the company. He set a $17 price target on Bloomin' Brands shares.
YETI Yeti
$18.66

0.25 (1.36%)

01/15/19
PIPR
01/15/19
NO CHANGE
Target $25
PIPR
Overweight
Piper ups Yeti target to $25, calls valuation 'very reasonable'
Piper Jaffray analyst Peter Keith views Yeti's preliminary Q4 results as strong and indicative of potential sales and margin upside the company can drive going forward. Importantly, high margin direct-to-consumer sales drove most of the upside, as Yeti appears to be leveraging its recently launched national advertising, Keith tells investors in a research note after meeting with management. He continues to view the stock's valuation as "very reasonable" given the company's "strong fundamentals." The analyst raised his price target for Yeti to $25 from $24 and reiterates an Overweight rating on the name.
01/15/19
BARD
01/15/19
NO CHANGE
Target $23
BARD
Outperform
Fresh Pick designation removed from Yeti, Outperform rating reiterated at Baird
Baird analyst Peter Benedict closed out his Fresh Pick designation on Yeti as his associated tactical catalysts have unfolded. The analyst said he continues to see significant upside opportunity for the shares longer-term as brand awareness grows and ongoing product innovation expands. Benedict reiterated his Outperform rating and $23 price target on Yeti shares.
01/14/19
JEFF
01/14/19
NO CHANGE
Target $35
JEFF
Buy
Yeti target raised to $35 after 'strong' Q4 at Jefferies
Yeti's preliminary Q4 results were strong, as the brand continues to gain credibility in non-core categories and mix shifts favorably to direct-to-consumer, Jefferies analyst Randal Konik tells investors in a post-earnings research note. The analyst sees "significant opportunity" for Yeti to expand its total addressable market and boosted his price target for the shares to $35 from $34. He keeps a Buy rating on the name.
01/14/19
BARD
01/14/19
NO CHANGE
Target $23
BARD
Outperform
Yeti bullish thesis reinforced by Q4 update, says Baird
Baird analyst Peter Benedict noted Yeti provided a positive Q4 update which he said reinforces his bullish thesis. The analyst believes the company is on track to be a $1B brand within the next 2-3 years as rising brand awareness, ongoing product innovation, and a broadening geographic footprint will support its growth. Benedict reiterated his Outperform rating and $23 price target on Yeti shares.
AVP Avon Products
$2.90

0.16 (5.84%)

09/24/18
09/24/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Plains All American (PAA) and Plains GP Holdings (PAGP) were upgraded to Buy from Hold at Stifel. 2. Avon Products (AVP) upgraded to Buy from Neutral at DA Davidson with analyst Linda Bolton Weiser citing the increased "sense of urgency" under the new CEO Jan Zijderveld displayed in his first analyst meeting, demonstrating his greater engagement in the company's operations, hiring of executives with sales experience, and "establishing a culture of accountability." 3. United Natural Foods (UNFI) upgraded to Sector Perform at RBC Capital with analyst William Kirk saying while core business challenges for the company remain and the risk of the Supervalu acquisition integration continues, its 6.4-times earnings valuation likely accounts for these issues. 4. KVH Industries (KVHI) upgraded to Buy from Neutral at Chardan with analyst James McIlree saying he expects "continued strong growth" from its Agile Plans that should result in improved margins and increased financial predictability. 5. RELX (RELX) upgraded to Overweight from Equal Weight at Barclays with analyst Nick Dempsey saying he views the current valuation as attractive. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/24/18
DADA
09/24/18
UPGRADE
Target $3.5
DADA
Buy
Avon Products upgraded to Buy at DA Davidson on operational focus of new CEO
As reported earlier, DA Davidson analyst Linda Bolton Weiser upgraded Avon Products (AVP) to Buy from Hold and raised her price target to $3.50 from $1.75. The analyst cites the increased "sense of urgency" under the new CEO Jan Zijderveld displayed in his first analyst meeting, demonstrating his greater engagement in the company's operations, hiring of executives with sales experience, and "establishing a culture of accountability". Based on her increased confidence in Avon's management team, Weiser also raised her target enterprise value to expected FY20 EBITDA target multiple to 6.5-times from 4.5-times, which is still a discount to other direct sellers like Nu Skin (NUS) and Herablife (HLF) trading at 11- to 12-times
09/24/18
DADA
09/24/18
UPGRADE
DADA
Buy
Avon Products upgraded to Buy from Neutral at DA Davidson
09/18/18
DADA
09/18/18
NO CHANGE
DADA
Neutral
Avon CEO likely to get time before board considers sale, says DA Davidson
DA Davidson analyst Linda Bolton Weiser thinks the board of Avon Products (AVP) will give new CEO Jan Zijderveld a period of time to improve financial performance before seriously considering a sale of the company. With Zijderveld set to unveil his turnaround strategy on September 21, the Wall Street Journal reported last night that Brazilian beauty direct seller Natura recently approached Avon about a takeover, Bolton Weiser tells investors in a research note titled "What Will Become of Avon?" Natura said in a statement, however, that there are no negotiations in progress concerning a possible acquisition of Avon, the analyst points out. She doubts that the board and Cerberus would find it prudent to sell the company when the share price is around $2. With that said, Bolton Weiser notes that Avon's takeout valuation is $7.75 per share based on Coty's (COTY) 2012 offer. In April 2012, Coty offered $23.25 per share for Avon, a 27% premium, and later raised it to $24.75 per share, or $10.7B, the analyst recalls. She notes the offer was withdrawn in May 2012. Bolton Weiser has a Neutral rating on Avon Products with a $1.75 price target. The stock in late morning trading is up 8%, or 16c, to $2.24.

TODAY'S FREE FLY STORIES

ETFC

E-Trade

$47.45

0.88 (1.89%)

17:33
02/17/19
02/17
17:33
02/17/19
17:33
Conference/Events
E-Trade to hold Education Day »

Education Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

PFE

Pfizer

$42.41

0.45 (1.07%)

12:56
02/17/19
02/17
12:56
02/17/19
12:56
Hot Stocks
Pfizer, EMD Serono announce publication of Phase 3 data for BAVENCIO plus INLYTA »

Merck KGaA, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 18

    May

MRK

Merck

$79.84

0.9 (1.14%)

, PFE

Pfizer

$42.41

0.45 (1.07%)

12:48
02/17/19
02/17
12:48
02/17/19
12:48
Hot Stocks
Merck presents results from Phase 3 KEYNOTE-426 study »

Merck (MRK) announced…

MRK

Merck

$79.84

0.9 (1.14%)

PFE

Pfizer

$42.41

0.45 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 11

    Apr

  • 18

    May

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

12:42
02/17/19
02/17
12:42
02/17/19
12:42
Hot Stocks
Aveo Pharmaceuticals presents TIVO-3 trial topline results »

Aveo Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARDM

Aradigm

$0.00

(0.00%)

12:34
02/17/19
02/17
12:34
02/17/19
12:34
Hot Stocks
Aradigm announces plans for reorganization under Chapter 11 »

Aradigm has filed for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

, XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

13:26
02/16/19
02/16
13:26
02/16/19
13:26
Periodicals
Amazon a risk for almost every stock/sector, Barron's says »

Amazon (AMZN) is eating…

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

KR

Kroger

$29.50

0.54 (1.86%)

FAST

Fastenal

$62.97

0.61 (0.98%)

GWW

Grainger

$316.63

4.9 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

YETI

Yeti

$22.85

0.97 (4.43%)

13:20
02/16/19
02/16
13:20
02/16/19
13:20
Periodicals
Yeti stock has 60% upside, Barron's says »

Yeti Holdings stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

L

Loews

$46.67

0.785 (1.71%)

13:14
02/16/19
02/16
13:14
02/16/19
13:14
Periodicals
Investors can love Loews, Barron's says »

Loews is a $15B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 28

    May

EQIX

Equinix

$421.53

1.16 (0.28%)

, COR

CoreSite Realty

$102.69

0.625 (0.61%)

13:10
02/16/19
02/16
13:10
02/16/19
13:10
Periodicals
Equinix, CoreSite Realty among stocks to play data-center boom, Barron's says »

Data-center stocks may…

EQIX

Equinix

$421.53

1.16 (0.28%)

COR

CoreSite Realty

$102.69

0.625 (0.61%)

IRM

Iron Mountain

$35.13

-0.14 (-0.40%)

INXN

Interxion

$64.65

0.81 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 26

    Mar

  • 26

    Mar

NOK

Nokia

$6.31

0.015 (0.24%)

, ERIC

Ericsson

$9.36

0.015 (0.16%)

13:07
02/16/19
02/16
13:07
02/16/19
13:07
Periodicals
A U.S. ban of Huawei may benefit Ericsson, Samsung, Barron's says »

The next salvo in the…

NOK

Nokia

$6.31

0.015 (0.24%)

ERIC

Ericsson

$9.36

0.015 (0.16%)

SSNLF

Samsung

$0.00

(0.00%)

CSCO

Cisco

$49.45

1.05 (2.17%)

JNPR

Juniper

$27.12

0.16 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

COP

ConocoPhillips

$70.13

1.04 (1.51%)

, MUR

Murphy Oil

$29.23

0.59 (2.06%)

13:00
02/16/19
02/16
13:00
02/16/19
13:00
Periodicals
Dividend investors should look to oil stocks for big yields, Barron's says »

Energy stocks aren't…

COP

ConocoPhillips

$70.13

1.04 (1.51%)

MUR

Murphy Oil

$29.23

0.59 (2.06%)

CVX

Chevron

$119.30

1.19 (1.01%)

VLO

Valero

$84.34

0.75 (0.90%)

XOM

Exxon Mobil

$77.74

1.47 (1.93%)

MRO

Marathon Oil

$17.07

0.15 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 07

    Mar

  • 18

    Mar

  • 22

    May

  • 28

    May

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

12:45
02/16/19
02/16
12:45
02/16/19
12:45
Periodicals
Protestors against NY's Amazon HQ2 got math wrong, Barron's says »

On Thursday, Amazon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

, NDAQ

Nasdaq

$87.74

0.56 (0.64%)

12:28
02/16/19
02/16
12:28
02/16/19
12:28
Periodicals
Investors interested in U.S. cannabis companies face challenges, Barron's says »

Investors interested in…

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

NDAQ

Nasdaq

$87.74

0.56 (0.64%)

CGC

Canopy Growth

$47.54

1.49 (3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 28

    May

  • 15

    Feb

AMD

AMD

$23.68

0.55 (2.38%)

, INTC

Intel

$51.64

0.85 (1.67%)

08:43
02/16/19
02/16
08:43
02/16/19
08:43
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMD

AMD

$23.68

0.55 (2.38%)

INTC

Intel

$51.64

0.85 (1.67%)

MRVL

Marvell

$18.82

-0.37 (-1.93%)

MCHP

Microchip

$91.10

0.49 (0.54%)

MU

Micron

$41.99

-0.23 (-0.54%)

NVDA

Nvidia

$157.22

2.69 (1.74%)

QCOM

Qualcomm

$51.97

0.42 (0.81%)

TXN

Texas Instruments

$107.55

0.57 (0.53%)

TWTR

Twitter

$31.23

0.28 (0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 07

    Mar

  • 07

    Mar

  • 25

    Mar

  • 26

    Mar

  • 28

    May

  • 04

    Jun

  • 05

    Jun

AMGN

Amgen

$188.31

1.6 (0.86%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

04:55
02/16/19
02/16
04:55
02/16/19
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2019 ASCO Genitourinary…

AMGN

Amgen

$188.31

1.6 (0.86%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

AZN

AstraZeneca

$40.92

0.93 (2.33%)

BAYRY

Bayer

$0.00

(0.00%)

BMY

Bristol-Myers

$51.64

0.81 (1.59%)

CALA

Calithera Biosciences

$5.35

0.14 (2.69%)

CLVS

Clovis

$25.44

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

ESALY

Eisai

$0.00

(0.00%)

EXEL

Exelixis

$22.26

-0.05 (-0.22%)

IMMU

Immunomedics

$14.23

0.225 (1.61%)

INO

Inovio

$3.70

0.01 (0.27%)

MRK

Merck

$79.84

0.9 (1.14%)

MYOV

Myovant Sciences

$21.48

0.1 (0.47%)

MYGN

Myriad Genetics

$31.41

0.53 (1.72%)

NH

NantHealth

$0.60

(0.00%)

NVS

Novartis

$89.89

0.865 (0.97%)

PFE

Pfizer

$42.41

0.45 (1.07%)

PGNX

Progenics

$4.87

0.13 (2.74%)

SGEN

Seattle Genetics

$71.48

2.92 (4.26%)

SNY

Sanofi

$42.51

0.94 (2.26%)

TYME

Tyme Technologies

$3.19

0.055 (1.76%)

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 16

    Feb

  • 19

    Feb

  • 20

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

  • 11

    Mar

  • 22

    Mar

  • 11

    Apr

  • 28

    Apr

  • 18

    May

  • 20

    May

WES

Western Gas Partners

$49.52

0.38 (0.77%)

, WGP

Western Gas Equity

$32.38

0.2 (0.62%)

19:30
02/15/19
02/15
19:30
02/15/19
19:30
Recommendations
Western Gas Partners, Western Gas Equity analyst commentary at MUFG »

MUFG raises price targets…

WES

Western Gas Partners

$49.52

0.38 (0.77%)

WGP

Western Gas Equity

$32.38

0.2 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 15

    Feb

  • 04

    Mar

PXD

Pioneer Natural

$145.33

2.27 (1.59%)

19:19
02/15/19
02/15
19:19
02/15/19
19:19
Recommendations
Pioneer Natural analyst commentary at MUFG »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

ZTS

Zoetis

$95.38

2.16 (2.32%)

18:42
02/15/19
02/15
18:42
02/15/19
18:42
Hot Stocks
Zoetis CEO says: 'Diagnostics are more important in animals than humans' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$136.40

2.13 (1.59%)

18:22
02/15/19
02/15
18:22
02/15/19
18:22
Hot Stocks
Johnson & Johnson CEO: 'We ended 2018 with great results' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 25

    Feb

  • 25

    Feb

  • 06

    Mar

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

18:18
02/15/19
02/15
18:18
02/15/19
18:18
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

18:14
02/15/19
02/15
18:14
02/15/19
18:14
Hot Stocks
Biohaven treatment of multiple system atrophy granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$188.31

1.6 (0.86%)

18:11
02/15/19
02/15
18:11
02/15/19
18:11
Hot Stocks
Amgen treatment of Acute Myeloid Leukemia granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$100.19

1.19 (1.20%)

18:02
02/15/19
02/15
18:02
02/15/19
18:02
Hot Stocks
Celanese announces Acetyl Intermediates price increases in China »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

17:58
02/15/19
02/15
17:58
02/15/19
17:58
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

GLD

SPDR Gold Shares

$124.81

0.77 (0.62%)

17:41
02/15/19
02/15
17:41
02/15/19
17:41
Hot Stocks
SPDR Gold Shares holdings fall to 793.03MT from 796.85MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.